Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy

Fernie J.A. Penning-van Beest, Irene D. Bezemer, Elisabeth Smits, Luis A. García Rodríguez, Lucía Cea Soriano, Francesco Lapi, Monica Simonetti, Alex Asiimwe, Ron M.C. Herings

Research output: Contribution to journalArticleAcademicpeer-review


Objectives: To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. Study design: This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy. Results: The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time. Conclusion: Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.

Original languageEnglish
Pages (from-to)243-245
Number of pages3
Issue number4
Publication statusPublished - Oct 2020


  • Acne
  • Cyproterone acetate/ethinylestradiol
  • Diane-35
  • Prescribing
  • Real world data
  • Risk minimization

Cite this